BofA raised the firm’s price target on Arvinas (ARVN) to $12 from $10 and keeps a Neutral rating on the shares after the company presented new phase 1 results for ARV-102 that showed “encouraging” pharmacodynamics and “strong” biomarker activity. The firm is “encouraged” by these results, which it says establish early biological proof-of-concept for the oral brain-penetrant PROTAC degrader of LRRK2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Announces Positive Phase 1 Trial Results
- Arvinas presents data from two Phase 1 trials for ARV-102
- Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls
- Arvinas downgraded to Neutral from Buy at BofA
- Arvinas Holding: Strategic Shifts and Cost Optimization Amidst Competitive SERD Landscape